Additionally, the potential impact of NOACs on the progression of conditions like colorectal cancer, as seen with edoxaban’s superior ability to suppress tumor growth and mitigate elevated levels of inflammatory markers, including PAR2, signal transducer and activator of transcription-3 (STAT3), cyclin D1, and Ki67, warrants further exploration to elucidate the broader implications of these findings for clinical practice [281]. The gene discussed is STAT3; the disease is neoplasm.